9 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Ionis Pharmaceuticals, revealing an average target of $64.67, a high estimate of $75.00, and a low estimate of $55.00. Surpassing the previous average price target of $62.71, the current average has increased by 3.13%.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Ionis Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into Ionis Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Ionis Pharmaceuticals analyst ratings.

Delving into Ionis Pharmaceuticals's Background

Breaking Down Ionis Pharmaceuticals's Financial Performance

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Positive Revenue Trend: Examining Ionis Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 113.65% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Ionis Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -2.85%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Ionis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.64%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.31%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 3.76. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Basics of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.